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Containing contraceptive costs
There are about 7 billion people living on our planet. 
In many countries resources are strained and we seek 
to slow down the rate of population growth. There are 
obviously many factors that lead to rapid population 
growth. Contraceptive methods are an important 
means of slowing population growth by helping people limit and/or 
space their families. While the cost of older methods such as the oral 
contraceptive pill, injectable progestogens and copper intrauterine 
contraceptive devices (IUCDs) has come down considerably, the cost 
of the newer hormone-based long-acting reversible contraceptive 
(LARC) methods has not.
It is now generally accepted that LARC methods are most 
effective in preventing unwanted pregnancy, because their use does 
not demand daily compliance.[1] While the copper-based IUCDs 
remain effective and are very cost-effective, they generally have 
more side-effects (including excessive bleeding) than the subdermal 
etonogestrel-based implant (Implanon) and levonorgestrel-based 
Norplant, and the levonorgestrel intrauterine systems (IUSs) Mirena 
and Skyla/Jaydess (the latter not currently available in South Africa). 
Use of the Implanon and Mirena is increasing and bringing with it 
increased costs to both government and third party and individual 
payers. Are we paying too much – not because the manufacturer is 
overcharging, but because we are not fully utilising the lifetime of 
these products?
The evidence that copper IUCDs can be used well beyond their 
registered lifetimes is not new.[2] While there are practical costs 
associated with changing these products at the specified intervals, and 
attendant clinical risks, it is with the hormone-based LARC methods 
that the potential savings are greatest. Unlike copper IUCDs, which 
in some countries are very cheap, the hormone-based LARCs are 
universally expensive. A new study from St Louis, USA, has evalua-
ted using the Mirena for an extra year beyond its recommended 
life time.[3] A total of 263 women completed an additional 197.7 
woman-years of follow-up. There was one pregnancy, giving a failure 
rate of 0.51% (95% confidence interval 0.01 - 2.82). The etonogestrel 
implant was also evaluated for an additional year by measuring 
serum etonogestrel levels. The median and range of etonogestrel 
levels were 188.8 pg/ml (63.8 - 806.6) at 3 years of use, and 177.0 pg/
ml (67.9  - 470.5) at 4 years. Etonogestrel levels were unrelated to 
body mass index. This supplements a previous clinical study of the 
etonogestrel implant beyond 3 years of use.[4]
The situation with the Mirena is interesting in that it contains 
52 mg of levonorgestrel. Initially the release rate of levonorgestrel is 
~20 µg/d, declining to ~10 µg/d at the end of its 5-year lifespan. The 
Skyla/Jaydess contains 13.5 mg of levonorgestrel, which is initially 
released at the rate of ~10 µg/d, declining to ~5 µg/d at the end of 
its 3-year lifespan. In the USA the Skyla is promoted as a ‘low-dose’ 
IUS for women and healthcare providers who think that the Mirena 
is capable of producing side-effects such as weight gain, depression, 
mood swings, acne and fluid retention. In reality, its narrow presenting 
diameter allows it to negotiate the nulliparous cervix easily and its 
smaller frame fits the smaller nulliparous uterine cavity.[5] If the Skyla 
IUS remains effective at a release rate of 5 µg/d, it is logical to assume 
that the Mirena would as well. This suggests that the Mirena may be 
fully effective well beyond its current 5-year lifespan. The good news 
is that women who delay or fail to return for follow-up are likely to 
be protected against pregnancy for a considerable time, and that if 
they desire a pregnancy they will present for removal of the device. 
The dilemma remains for the clinician who sees users who return 
timeously. She/he is trapped between the Scylla of wanting to save the 
patient or the third-party payer a substantial sum of money, and the 
Charybdis of complying with the licence specifics of the product.
How do we explain to our method users that the lifespan of 
these products is really fairly arbitrary, and that the manufacturer 
evaluates safety and efficacy for a certain timespan that seems 
reasonable? The process of testing to find the near limit of any 
medical products utility would be time consuming, expensive and 
unethical. When independent evidence emerges that a product 
lifespan is indeed longer than the licence dictates, manufacturers 
rarely go to the expense of getting a new licence, especially if it 
is against their financial interests. Wu and Pickle[2] provide some 
controversial guidelines for the extended use of IUCDs. In the end, 
as always, clinicians have to use their clinical judgement. We should 
replace the device for users who seem concerned, and support users 
who request extended use either because they have heard about it 
elsewhere or because it is suggested to them. Some will be natural 
candidates for extended use, either because they are older and have 
declining fertility or because they are considering the use of another 
method or sterilisation.
While existing manufacturers are unlikely to make changes to their 
existing products, if the experience of the copper-based IUCDs over 
the past 40 years is repeated, new and generic manufacturers will use 
these new data in order to capture market share. Cheaper and longer-
acting hormonal LARC methods are on the way.
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